Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/33465
Title: Cabotegravir is not associated with weight gain in HIV-uninfected individuals in HPTN 077
Authors: Landovitz, Raphael J.
Zangeneh, Sahar Z.
Chau, Gordon
Grinsztejn, Beatriz
Eron, Joseph J.
Dawood, Halima
Magnus, Manya
Liu, Albert Y.
Panchia, Ravindre
Hosseinipour, Mina C.
Kofron, Ryan
Margolis, David A.
Rinehart, Alex
Adeyeye, Adeola
Burns, David
McCauley, Marybeth
Cohen, Myron S.
Currier, Judith S.
Affilliation: University of California. Center for Clinical AIDS Research & Education. Los Angeles, CA, USA.
Fred Hutchinson Cancer Research Center. Statistical Center for HIV/AIDS Research and Prevention. Seattle, WA, USA.
Fred Hutchinson Cancer Research Center. Statistical Center for HIV/AIDS Research and Prevention. Seattle, WA, USA.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
University of North Carolina. Division of Infectious Diseases. Chapel Hill, NC, United States.
University of KwaZulu Natal. Centre for the AIDS Programme of Research in South Africa. Durban, South Africa.
George Washington University. Milken Institute School of Public Health. Department of Epidemiology and Biostatistics. Washington DC, USA.
San Francisco Department of Public Health. Population Health Division. Bridge HIV. San Francisco, CA, USA.
University of the Witwatersrand. Chris Hani Baragwanath Academic Hospital. Perinatal HIV Research Unit. Soweto, South Africa.
University of North Carolina. Malawi Project. Lilongwe, Malawi.
University of California. Center for Clinical AIDS Research & Education. Los Angeles, CA, USA.
ViiV Healthcare. Durham, NC, USA.
ViiV Healthcare. Durham, NC, USA.
National Institutes of Health. National Institute of Allergy and Infectious Disease. Division of AIDS. Rockville, MD, USA.
National Institutes of Health. National Institute of Allergy and Infectious Disease. Division of AIDS. Rockville, MD, USA.
FHI360. Durham, NC, USA.
University of North Carolina. Division of Infectious Diseases. Chapel Hill, NC, USA.
University of California, Los Angeles. Center for Clinical AIDS Research & Education. Los Angeles, CA, USA.
Abstract: Studies in HIV-infected individuals suggest excess weight gain with integrase inhibitor-based antiretroviral therapy. HPTN 077 evaluated changes in weight and fasting metabolic parameters in HIV-uninfected individuals randomized to cabotegravir or a placebo. No differences between arms were found for change in weight or fasting metabolic parameters overall or for subgroups.
Keywords: Cabotegravir
CAB
Weight gain
HIV uninfected
Issue Date: 2019
Publisher: Oxford University Press
Citation: LANDOVITZ, Raphael J. et al. Cabotegravir is not associated with weight gain in HIV-uninfected Individuals in HPTN 077. Clinical Infectious Diseases, p. 1-16, May 2019.
DOI: 10.1093/cid/ciz439
ISSN: 1058-4838
Copyright: open access
Appears in Collections:INI - Preprint

Files in This Item:
File Description SizeFormat 
Cabotegravir_Beatriz_Grinsztejn_INI_Lapclin-AIDS_2019.pdf314.86 kBAdobe PDF    Request a copy



FacebookTwitterDeliciousLinkedInGoogle BookmarksBibTex Format mendeley Endnote DiggMySpace

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.